Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (10602) 10602
Publication (608) 608
Book Review (106) 106
Magazine Article (63) 63
Conference Proceeding (30) 30
Book Chapter (27) 27
Book / eBook (23) 23
Dissertation (9) 9
Reference (8) 8
Web Resource (7) 7
Data Set (3) 3
Streaming Video (3) 3
Government Document (1) 1
Newspaper Article (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (8948) 8948
antiparkinson agents - therapeutic use (6244) 6244
parkinson disease - drug therapy (6136) 6136
male (5661) 5661
female (4703) 4703
parkinson's disease (4204) 4204
middle aged (3940) 3940
clinical neurology (3894) 3894
aged (3851) 3851
index medicus (3445) 3445
antiparkinson agents - adverse effects (3138) 3138
levodopa - therapeutic use (3038) 3038
animals (2515) 2515
neurosciences (2490) 2490
antiparkinson agents - pharmacology (1932) 1932
antiparkinson agents - administration & dosage (1922) 1922
parkinson disease - physiopathology (1920) 1920
levodopa (1895) 1895
levodopa - adverse effects (1744) 1744
adult (1654) 1654
pharmacology & pharmacy (1436) 1436
parkinson disease - complications (1221) 1221
treatment outcome (1184) 1184
rats (1161) 1161
levodopa - administration & dosage (1156) 1156
parkinsons-disease (1028) 1028
dopamine (974) 974
drug therapy, combination (923) 923
dose-response relationship, drug (918) 918
aged, 80 and over (883) 883
l-dopa (851) 851
parkinson disease - therapy (845) 845
neurology (829) 829
dopa (791) 791
severity of illness index (762) 762
time factors (738) 738
parkinson disease - diagnosis (732) 732
parkinson disease - psychology (707) 707
psychiatry (701) 701
dopamine agonists - therapeutic use (675) 675
levodopa - pharmacology (662) 662
basal ganglia (661) 661
motor fluctuations (647) 647
disease models, animal (644) 644
double-blind (640) 640
parkinsons disease (598) 598
dopamine - metabolism (595) 595
parkinson disease - metabolism (567) 567
parkinsonian disorders - drug therapy (565) 565
double-blind method (562) 562
antiparkinson agents - pharmacokinetics (553) 553
analysis (545) 545
motor activity - drug effects (539) 539
disease (537) 537
parkinson disease (511) 511
mice (509) 509
dyskinesia (507) 507
drug combinations (500) 500
dyskinesia, drug-induced - etiology (478) 478
deep brain stimulation (475) 475
therapy (466) 466
movement disorders (460) 460
rats, sprague-dawley (451) 451
antiparkinson agents (449) 449
follow-up studies (437) 437
subthalamic nucleus (430) 430
drug therapy (425) 425
disease progression (418) 418
carbidopa - therapeutic use (416) 416
risk factors (402) 402
drug administration schedule (392) 392
brain (389) 389
care and treatment (383) 383
dopamine agonists - adverse effects (378) 378
quality of life (363) 363
parkinson disease - pathology (362) 362
corpus striatum - drug effects (355) 355
surgery (355) 355
parkinson disease - epidemiology (354) 354
neurons (353) 353
medicine, general & internal (344) 344
brain - drug effects (342) 342
research (342) 342
antiparkinsonian agents (336) 336
analysis of variance (335) 335
retrospective studies (335) 335
levodopa - pharmacokinetics (334) 334
dyskinesia, drug-induced - drug therapy (331) 331
pramipexole (331) 331
carbidopa - administration & dosage (330) 330
neuropsychological tests (330) 330
clinical trials as topic (324) 324
corpus striatum - metabolism (323) 323
magnetic resonance imaging (320) 320
drug interactions (315) 315
pharmacokinetics (314) 314
dementia (313) 313
substantia-nigra (308) 308
prevalence (307) 307
dopamine agents - therapeutic use (303) 303
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (18) 18
Online Resources - Online (8) 8
Collection Dvlpm't (Acquisitions) - Vendor file (4) 4
Baycrest Hospital - Stacks (1) 1
Baycrest Hospital - Wellness Library (1) 1
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9436) 9436
German (284) 284
French (223) 223
Spanish (202) 202
Russian (156) 156
Japanese (132) 132
Polish (50) 50
Dutch (35) 35
Hungarian (33) 33
Italian (29) 29
Danish (24) 24
Chinese (21) 21
Norwegian (20) 20
Swedish (18) 18
Portuguese (13) 13
Finnish (11) 11
Hebrew (8) 8
Czech (7) 7
Romanian (7) 7
Serbian (4) 4
Ukrainian (2) 2
Bosnian (1) 1
Croatian (1) 1
Icelandic (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Exosomes as drug delivery vehicles for Parkinson's disease therapy
by Haney, Matthew J and Klyachko, Natalia L and Zhao, Yuling and Gupta, Richa and Plotnikova, Evgeniya G and He, Zhijian and Patel, Tejash and Piroyan, Aleksandr and Sokolsky, Marina and Kabanov, Alexander V and Batrakova, Elena V
Journal of Controlled Release, ISSN 0168-3659, 06/2015, Volume 207, pp. 18 - 30
Exosomes are naturally occurring nanosized vesicles that have attracted considerable attention as drug delivery vehicles in the past few years. Exosomes are... 
Oxidative stress | Neuroinflammation | Parkinson's disease | Catalase | Exosomes | Blood–brain barrier | Blood-brain barrier | ALZHEIMERS-DISEASE | REPEATED INJECTIONS | MACROPHAGE DELIVERY | MEDIATED TRANSFER | BLOOD-BRAIN-BARRIER | BIOLOGICAL BARRIERS | CHEMISTRY, MULTIDISCIPLINARY | IN-VITRO | PEGYLATED LIPOSOMES | PHARMACOLOGY & PHARMACY | SUPEROXIDE-DISMUTASE | Antioxidants - chemistry | Antioxidants - metabolism | Oxidopamine | Anti-Inflammatory Agents - metabolism | PC12 Cells | Neuroprotective Agents - metabolism | Drug Carriers | Brain - metabolism | Nanoparticles | Parkinsonian Disorders - metabolism | Parkinsonian Disorders - drug therapy | Antiparkinson Agents - chemistry | Anti-Inflammatory Agents - administration & dosage | Female | Neurons - metabolism | Neuroprotective Agents - administration & dosage | Nanomedicine | Disease Models, Animal | Neuroprotective Agents - chemistry | Mice, Inbred C57BL | Solubility | Rats | Technology, Pharmaceutical - methods | Parkinsonian Disorders - chemically induced | Administration, Intranasal | Chemistry, Pharmaceutical | Brain - drug effects | Catalase - metabolism | Catalase - administration & dosage | Animals | Anti-Inflammatory Agents - chemistry | Antioxidants - administration & dosage | RAW 264.7 Cells | Antiparkinson Agents - administration & dosage | Mice | Kinetics | Oxidative Stress - drug effects | Antiparkinson Agents - metabolism | Catalase - chemistry | Drugs | Drug delivery systems | Proteases | Analysis | Antiparkinsonian agents | Vehicles
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text 2-Azetidinone – A new profile of various pharmacological activities
by Mehta, Parul D and Sengar, N.P.S and Pathak, A.K
European Journal of Medicinal Chemistry, ISSN 0223-5234, 2010, Volume 45, Issue 12, pp. 5541 - 5560
2-Azetidinone, a β-lactam four member heterocyclic compound involved in research aimed to evaluate new products that possess interesting biological activities.... 
2-Azetidinone | β-Lactam | Biological activity | Four membered heterocyclic ring | 3,4-DISUBSTITUTED AZETIDINONES | CHEMISTRY, MEDICINAL | SOLID-PHASE SYNTHESIS | PROLIFERATOR-ACTIVATED RECEPTORS | beta-Lactam | HUMAN-LEUKOCYTE ELASTASE | HUMAN CYTOMEGALOVIRUS PROTEASE | MONOCYCLIC BETA-LACTAMS | CHOLESTEROL ABSORPTION | ANTIINFLAMMATORY AGENTS | CATHEPSIN-K | SELECTIVE INHIBITORS | Antifungal Agents - pharmacology | Animals | Antiparkinson Agents - pharmacology | Anti-Infective Agents - chemistry | Anti-Infective Agents - pharmacology | Humans | Antiparkinson Agents - chemistry | Antifungal Agents - chemistry | Hypoglycemic Agents - chemistry | Azetidines - pharmacology | Azetidines - chemistry | Hypoglycemic Agents - pharmacology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Anti-parkinsonism, hypoglycemic and anti-microbial activities of new poly fused ring heterocyclic candidates
by Al-Harbi, Naif O and Bahashwan, Saleh A and Fayed, Ahmed A and Aboonq, Moutasem S and Amr, Abd El-Galil E
International Journal of Biological Macromolecules, ISSN 0141-8130, 06/2013, Volume 57, pp. 165 - 173
A new series of poly fused pyrazolothienopyrimidine derivatives – were synthesized and their anti-parkinsonism, hypoglycemic and anti-microbial activities were... 
Heterocyclic candidates | Hypoglycemic and anti-microbial activities | Poly ring systems | Anti-parkinsonism | POLYMER SCIENCE | INFLAMMATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | THIENOPYRIMIDINES | INHIBITORS | CHEMISTRY, APPLIED | Antiparkinson Agents - pharmacology | Anti-Infective Agents - pharmacology | Heterocyclic Compounds, 2-Ring - chemistry | Antiparkinson Agents - chemical synthesis | Hypoglycemic Agents - chemistry | Candida albicans - growth & development | Anti-Infective Agents - chemical synthesis | Heterocyclic Compounds, 2-Ring - pharmacology | Hypoglycemic Agents - pharmacology | Bacteria - growth & development | Animals | Anti-Infective Agents - chemistry | Hypoglycemic Agents - chemical synthesis | Parkinson Disease, Secondary - drug therapy | Antiparkinson Agents - chemistry | Aspergillus fumigatus - growth & development | Mice | Parkinson Disease, Secondary - chemically induced | Heterocyclic Compounds, 2-Ring - chemical synthesis | Drugstores | Parkinson's disease | Pyridine | Antiparkinsonian agents | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Advances in the treatment of Parkinson's disease
by Singh, Neha and Pillay, Viness and Choonara, Yahya E
Progress in Neurobiology, ISSN 0301-0082, 2007, Volume 81, Issue 1, pp. 29 - 44
Parkinson's disease (PD) affects one in every 100 persons above the age of 65 years, making it the second most common neurodegenerative disease after... 
Current therapies | PD vaccine | Parkinson's disease (PD) | Drug delivery | Levodopa | Neuroprotective agents | Non-pharmacological treatments | Cell transplantation | Nicotine | nicotine | OXIDATIVE DAMAGE | neuroprotective | MAO-B INHIBITOR | drug delivery | ALPHA-SYNUCLEIN | DOPAMINERGIC-NEURONS | SUBSTANTIA-NIGRA | NEUROSCIENCES | current therapies | agents | cell transplantation | MOTOR FLUCTUATIONS | LEVODOPA-INDUCED DYSKINESIA | NEUROTROPHIC FACTOR GDNF | levodopa | non-pharmacological treatments | L-DOPA | DEEP BRAIN-STIMULATION | Neuroprotective Agents - therapeutic use | Parkinson Disease - therapy | Genetic Therapy | Nicotine - therapeutic use | Humans | Vaccination | Dopamine Agonists - therapeutic use | Parkinson Disease - drug therapy | Antiparkinson Agents - therapeutic use | Stem Cell Transplantation | Fetal Tissue Transplantation | Parkinsonian Disorders - drug therapy | Deep Brain Stimulation | Anti-Inflammatory Agents - therapeutic use | Cholinergic Antagonists - therapeutic use | Iron Chelating Agents - therapeutic use | Brain Tissue Transplantation | Vitamins - therapeutic use | Antiparkinson Agents - adverse effects | Enzyme Inhibitors - therapeutic use | Parkinson Disease - surgery | Antioxidants - therapeutic use | Animals | Globus Pallidus - surgery | Parkinsonian Disorders - prevention & control | Antiparkinson Agents - classification | Nanotechnology | Drug therapy | Parkinson's disease
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text An update on pharmacological, pharmacokinetic properties and drug-drug interactions of rotigotine transdermal system in Parkinson's disease and restless legs syndrome
by Elshoff, Jan-Peer and Cawello, Willi and Andreas, Jens-Otto and Mathy, Francois-Xavier and Braun, Marina
Drugs, ISSN 0012-6667, 2015, Volume 75, Issue 5, pp. 487 - 501
This narrative review reports on the pharmacological and pharmacokinetic properties of rotigotine, a non-ergolinic D-3/D-2/D-1 dopamine receptor agonist... 
PLASMA-LEVELS | SAFETY | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | TOXICOLOGY | PLACEBO-CONTROLLED TRIAL | QUALITY-OF-LIFE | CLINICAL-FEATURES | OPEN-LABEL EXTENSION | LONG-TERM TREATMENT | DOPAMINE AGONIST ROTIGOTINE | PATCH | Thiophenes - therapeutic use | Restless Legs Syndrome - epidemiology | Thiophenes - adverse effects | Humans | Dopamine Agonists - therapeutic use | Tetrahydronaphthalenes - therapeutic use | Dopamine Agonists - adverse effects | Parkinson Disease - drug therapy | Thiophenes - administration & dosage | Tetrahydronaphthalenes - adverse effects | Restless Legs Syndrome - metabolism | Antiparkinson Agents - therapeutic use | Restless Legs Syndrome - drug therapy | Drug Interactions | Tetrahydronaphthalenes - administration & dosage | Parkinson Disease - epidemiology | Anti-Dyskinesia Agents - administration & dosage | Parkinson Disease - metabolism | Comorbidity | Dopamine Agonists - pharmacokinetics | Tetrahydronaphthalenes - pharmacokinetics | Evidence-Based Medicine | Antiparkinson Agents - adverse effects | Transdermal Patch - adverse effects | Antiparkinson Agents - pharmacokinetics | Anti-Dyskinesia Agents - therapeutic use | Thiophenes - pharmacokinetics | Animals | Anti-Dyskinesia Agents - adverse effects | Dopamine Agonists - administration & dosage | Antiparkinson Agents - administration & dosage | Anti-Dyskinesia Agents - pharmacokinetics | Practice Guidelines as Topic
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Hold Your Horses: Impulsivity, Deep Brain Stimulation, and Medication in Parkinsonism
by Michael J. Frank and Johan Samanta and Ahmed A. Moustafa and Scott J. Sherman
Science, ISSN 0036-8075, 11/2007, Volume 318, Issue 5854, pp. 1309 - 1312
Deep brain stimulation (DBS) of the subthalamic nucleus markedly improves the motor symptoms of Parkinson's disease, but causes cognitive side effects such as... 
Neurology | Basal ganglia | Health outcomes | Deep brain stimulation | Parkinson disease | Medications | Thalamus | Reports | Lesions | Behavioral neuroscience | Modeling | CHOICE | SUBTHALAMIC NUCLEUS | REACTION-TIME | OPTIMAL DECISION-MAKING | BASAL GANGLIA | MULTIDISCIPLINARY SCIENCES | DISEASE | DOPAMINE | HIGH-FREQUENCY STIMULATION | COGNITIVE CONTROL | SELECTION | Parkinson Disease - therapy | Impulsive Behavior - etiology | Humans | Middle Aged | Male | Reaction Time | Deep Brain Stimulation - adverse effects | Dopamine Agents - therapeutic use | Antiparkinson Agents - therapeutic use | Dopamine Agents - adverse effects | Learning | Levodopa - administration & dosage | Conflict (Psychology) | Female | Dopamine Agents - administration & dosage | Neural Networks (Computer) | Decision Making | Levodopa - therapeutic use | Reinforcement (Psychology) | Parkinson Disease - physiopathology | Parkinson Disease - psychology | Antiparkinson Agents - adverse effects | Basal Ganglia - physiology | Subthalamic Nucleus - physiology | Levodopa - adverse effects | Aged | Antiparkinson Agents - administration & dosage | Models, Neurological | Parkinsonism | Psychological aspects | Physiological aspects | Brain stimulation | Impulse | Health aspects | Brain | Side effects | Cognition & reasoning | Medical treatment | Parkinsons disease | Drug therapy
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's Disease
by Chen, Jack J., PharmD, BCPS, CGp and Swope, David M., MD and Dashtipour, Khashayar, MD, PhD
Clinical Therapeutics, ISSN 0149-2918, 2007, Volume 29, Issue 9, pp. 1825 - 1849
Abstract Background: Inhibitors of monoamine oxidase (MAO) with selectivity and specificity for MAO type B (MAO-B) prolong the duration of action of both... 
Internal Medicine | Medical Education | rasagiline | Parkinson's disease | propargylamine | neuroprotection | monoamine oxidase | selegiline | CONTROLLED-TRIAL | SEROTONIN SYNDROME | MAO-B INHIBITOR | MPTP-INDUCED NEUROTOXICITY | MOTOR FLUCTUATIONS | MITOCHONDRIAL PERMEABILITY TRANSITION | IN-VIVO | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | L-DEPRENYL | NEUROBLASTOMA SH-SY5Y CELLS | rasagilme | Indans - adverse effects | Neuroprotective Agents - therapeutic use | Antiparkinson Agents - pharmacology | Humans | Selegiline - pharmacology | Parkinson Disease - drug therapy | Indans - therapeutic use | Monoamine Oxidase Inhibitors - administration & dosage | Antiparkinson Agents - therapeutic use | Drug Interactions | Neuroprotective Agents - pharmacology | Indans - administration & dosage | Neuroprotective Agents - adverse effects | Drug Therapy, Combination | Neuroprotective Agents - administration & dosage | Selegiline - therapeutic use | Monoamine Oxidase Inhibitors - therapeutic use | Monoamine Oxidase Inhibitors - pharmacology | Selegiline - adverse effects | Monoamine Oxidase Inhibitors - adverse effects | Food-Drug Interactions | Antiparkinson Agents - adverse effects | Selegiline - administration & dosage | Antiparkinson Agents - administration & dosage | Indans - pharmacology | Oxidases | Medical colleges | Drug therapy | Analysis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Effect of a phytopharmaceutical medicine, Ginko biloba extract 761, in an animal model of Parkinson's disease: Therapeutic perspectives
by Rojas, Patricia, Ph.D and Montes, Pedro, M.Sc and Rojas, Carolina, B.Sc and Serrano-García, Norma, M.Sc and Rojas-Castañeda, Julio César, Ph.D
Nutrition, ISSN 0899-9007, 2012, Volume 28, Issue 11, pp. 1081 - 1088
Abstract Ginkgo Biloba extract 761 (EGb 761) is a patented and well-defined mixture of active compounds extracted from Ginkgo biloba leaves. This extract... 
Gastroenterology and Hepatology | Neuroprotection | Dopamine | Natural extract | Antioxidant | Recovery | OXIDATIVE STRESS | SUBSTANTIA-NIGRA NEURONS | LIPID-PEROXIDATION | STANDARDIZED EXTRACT | EGB761 PROTECTS | DOPAMINERGIC NEUROTOXICITY | NUTRITION & DIETETICS | SUPEROXIDE-DISMUTASE ACTIVITY | MONOAMINE-OXIDASE ACTIVITY | IN-VIVO | MOUSE CORPUS STRIATUM | Neuroprotective Agents - therapeutic use | Plant Extracts - chemistry | Antioxidants - chemistry | Oxidative Stress | Mesencephalon - metabolism | Humans | Anti-Inflammatory Agents, Non-Steroidal - chemistry | Dietary Supplements - analysis | Antiparkinson Agents - therapeutic use | Dopaminergic Neurons - metabolism | Antiparkinson Agents - chemistry | Parkinson Disease - metabolism | Dietary Supplements - adverse effects | Neuroprotective Agents - adverse effects | Phytotherapy | Parkinson Disease - diet therapy | Disease Models, Animal | Neuroprotective Agents - chemistry | Antiparkinson Agents - adverse effects | Antioxidants - therapeutic use | Parkinson Disease - prevention & control | Animals | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Antioxidants - adverse effects | Plant Extracts - therapeutic use | Apoptosis | Plant Extracts - adverse effects | Drugs | Antioxidants | Parkinson's disease | Neurons | Analysis | Medicine, Botanic | Medicine, Herbal | Health aspects | Isoflavones | Studies | Oxidative stress | Chinese medicine | Neurotoxicity | Free radicals | Acids | Neurodegeneration | Rodents | Dementia | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: The STRIDE-PD study
by Stocchi, Fabrizio and Rascol, Olivier and Kieburtz, Karl and Poewe, Werner and Jankovic, Joseph and Tolosa, Eduardo and Barone, Paulo and Lang, Anthony E and Olanow, C. Warren
Annals of Neurology, ISSN 0364-5134, 07/2010, Volume 68, Issue 1, pp. 18 - 27
Objective: L-dopa is the most widely used and most effective therapy for Parkinson disease (PD), but chronic treatment is associated with motor complications... 
MOTOR FLUCTUATIONS | DUODENAL INFUSION | 5-YEAR | MULTICENTER | LEVODOPA INFUSIONS | L-DOPA | DYSKINESIA INDUCTION | ROPINIROLE | PRIMATES | NEUROSCIENCES | PROGRESSION | CLINICAL NEUROLOGY | Humans | Middle Aged | Male | Risk | Parkinson Disease - drug therapy | Dopamine Agents - therapeutic use | Antiparkinson Agents - therapeutic use | Dopamine Agents - adverse effects | Enzyme Inhibitors - administration & dosage | Nitriles - administration & dosage | Carbidopa - therapeutic use | Levodopa - administration & dosage | Time Factors | Catechols - therapeutic use | Catechols - adverse effects | Carbidopa - adverse effects | Parkinson Disease - epidemiology | Female | Dopamine Agents - administration & dosage | Drug Therapy, Combination | Carbidopa - administration & dosage | Enzyme Inhibitors - adverse effects | Dyskinesia, Drug-Induced - epidemiology | Double-Blind Method | Levodopa - therapeutic use | Treatment Outcome | Antiparkinson Agents - adverse effects | Enzyme Inhibitors - therapeutic use | Disease Progression | Levodopa - adverse effects | Antiparkinson Agents - administration & dosage | Catechol O-Methyltransferase Inhibitors | Catechols - administration & dosage | Nitriles - adverse effects | Nitriles - therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights